2024年第四季度中东与非洲制药行业商业洞察报告(第三十五版)

Middle East & AfricaPharmaceutical Business Insights Thirty-Fifth Edition Report Release Date: Mar 2025Analytical Timeframe: MAT Dec 2024 © 2025. All rights reserved. IQVIA®is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Disclaimer IQVIA is not an “authorised person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) and does not provideinvestment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001 The forecasts, projections, and related information contained herein are made and provided subject to the assumptions, methodologies,caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. Nowarranty is made as to the completeness or accuracy of such third party sources or data This report, in part or in whole, is not intended to constitute investment advice, and is not a recommendation to purchase ornot purchase,an endorsement of, or an opinion as to the value of, any security or any investment instrument of any entity As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included hereinare subject tocertain risks and uncertainties, and are not to be considered guarantees of any particular outcome This report shall not be published, nor shall any public references to IQVIA be made regarding these services or this report,without IQVIA’prior written approval. When so provided, this report and the information herein must always be provided and used in its entirety, includingthis complete Disclaimer page This report is subject to the IQVIA General Terms and Conditions. Agenda +Newsletter report summary+Regional summary and analysis+Spotlight on new offering+Appendix Business insights snapshot MAT Q4 2024: Many countries have witnessedhigh growth in 2024 •Saudi Arabia leads the MEA region at$13.2Binvalue, expanded at16.1% PPGin value terms•UAE follows as the 2ndlargest, with$4.6 Bin valuehas seen a growth of16.2% PPG and 16.8%CAGR2 Among the key countries, KSA saw growth of 16.1% and continues to lead,accounting for 37.5% of sales in MEA Region South Africa1 United Arab Emirates (UAE) •South Africa has grown by 3.8% PPG accounting for $3.6 Bsaleswith theretail channel accounting for 82.4% oftotal sales•Cough & Cold Preparations TA continues to be Top TA at0.5% PPG and 6.3% share•Top 10 corporationsaccount for52%share in sales.AdcockIngram, a local firm, is leading with9.4%share andNovoNordiskbeing the fastest growing at26.6%PPG •UAE grew by 16.2.% PPG (fastest growing country in MEAregion**)accounting for $4.6 B sales•Top 10 TAsaccount for50.2%of total sales, whereinNewerGen Type II Antidiabetics TA is growing at 46.4% PPG•Top 10 corporationsaccount for48.7% sharein sales withEliLillybeing the fastest growing at62.3% PPG; mainly driven bytop brands likeMounjaro(95.2%), Cialis (8.5%), and Taltz(21.7%) on PPG Saudi Arabia (KSA) Egypt (EGY)* •Egypt volume sales has declined by-4.8% PPGdriven bygrowth fromRetail channel (0.78% PPG) accounting for82.4% of country’s Units sales•Systemic Antibacterialsis the top TA in Egypt with4.3%Units share whileAntihypertensives (1.5 PPG) is the fastestgrowingamongst the top 10 TAs•Top 10 corporations account for 43.4% sharein volumesales,Pharco is leadingthe sales with7.7% share and Apexisthe fastest growing corporation among top 10 corps(34.8%PPG) •Saudi Arabia has grown by 16.1% PPG, making it the secondfastest growing country in MEA, with sales valued at $13.2 B•Hospital channel (Hospitals + LPO) grew by 14.3% PPGandaccounting for49.8% of total sales•Top 10 corporationsaccount for45.3%share in sales. HikmaPharmais leading with6.5%shareand19.2%PPG•Jamjoom Pharma (21% PPG) is the fastest growing Local/Regcorpmainly driven by top brands likeAzi-Once (40.1%), Vitamin D3(11.4%), Hyfresh (57.4%) andRelaxon(20.5%) on PPG Algeria business in MEA is growing at 9.5% PPG mainly driven bylocal/regional players with 19.4% PPG Algeria (ALG) Fr. West Africa (FWA) FWA •Algeria retail channel sales increased by 9.5% PPGaccounting for$2.7 Bsales in MAT Q4 2024 period•Top TAs for AlgeriaareAntihypertensives(9.9% PPG) andInsulin & Analogs(-6.4% PPG).Allergy is the fastest growingTA at 14.8% PPG amongst the top 10 TAs•MS Pharma is the top corporationin Algeria with7.1% ofsales shareandBiocareBiotech SPhas penetrated among thetop 10corporations attributing toGlarus&NormotropeSales•Amongst the top products ofMS PharmalikeExval(14.3%PPG),Arovan(0.6% PPG),andUnirox(13.3% PPG) •FWA retail channel has grown by 6.5% PPG accounting for$1.8 B sales inMAT Q4 2024•Local/Regional playersgrew by9.7% PPGwhile accountingfor51% of total sales•Amongst the top 10 corporations,Sanoficontinues to be thetopselling corporation with6.4% sharewhilePharma 5 is thefastest growing top corporation at 16.4% PPGamongst thetop 10 corp